What It Is, Who Should Get Tested, and What Results Mean
Cancer Research
Genomic Testing
Precision Medicine
Share this BLOG article
Hereditary ovarian cancer syndrome refers to an inherited genetic condition that significantly raises a person's lifetime risk of developing ovarian cancer. If ovarian cancer has appeared in your family, or if you have been told you may be at higher risk, genetic testing can tell you whether one of these inherited gene changes is part of the picture.
For people who qualify, this is not a speculative step. It is something major clinical guidelines recommend, with real options available, no matter what the result shows.
This article explains what hereditary ovarian cancer syndrome is, who should consider testing, what the testing process looks like, and how to navigate results, including what next steps are for a positive result.
Understanding how inherited gene changes influence overall cancer risk starts with a broader look at how hereditary cancer works across different cancer types.
Genes Associated With Hereditary Ovarian Cancer Syndrome
Lifetime ovarian cancer risk for the general population: 1.2%
Gene
Syndrome / Condition
Lifetime Ovarian Cancer Risk
BRCA1
HBOC syndrome — CDC Tier 1
36–44%
BRCA2
HBOC syndrome — CDC Tier 1
11–17%
MLH1
Lynch syndrome — CDC Tier 1
4–12% (varies by gene)
MSH2
Lynch syndrome — CDC Tier 1
4–12%
MSH6
Lynch syndrome — CDC Tier 1
~1–11%
BRIP1
Moderate hereditary ovarian risk
~5–10%
RAD51C
Moderate hereditary ovarian risk
Growing evidence — included in comprehensive panels
RAD51D
Moderate hereditary ovarian risk
Growing evidence — included in comprehensive panels
BRCA1
Syndrome / Condition
HBOC syndrome — CDC Tier 1
Lifetime Ovarian Cancer Risk
36–44%
BRCA2
Syndrome / Condition
HBOC syndrome — CDC Tier 1
Lifetime Ovarian Cancer Risk
11–17%
MLH1
Syndrome / Condition
Lynch syndrome — CDC Tier 1
Lifetime Ovarian Cancer Risk
4–12% (varies by gene)
MSH2
Syndrome / Condition
Lynch syndrome — CDC Tier 1
Lifetime Ovarian Cancer Risk
4–12%
MSH6
Syndrome / Condition
Lynch syndrome — CDC Tier 1
Lifetime Ovarian Cancer Risk
~1–11%
BRIP1
Syndrome / Condition
Moderate hereditary ovarian risk
Lifetime Ovarian Cancer Risk
~5–10%
RAD51C
Syndrome / Condition
Moderate hereditary ovarian risk
Lifetime Ovarian Cancer Risk
Growing evidence — included in comprehensive panels
RAD51D
Syndrome / Condition
Moderate hereditary ovarian risk
Lifetime Ovarian Cancer Risk
Growing evidence — included in comprehensive panels
A BRCA-only test identifies BRCA1 and BRCA2 mutations only. All other genes in this table require a comprehensive multi-gene panel to detect mutations known to increase cancer risk.
Source: NCI BRCA Fact Sheet, CDC, NCI
What Is Hereditary Ovarian Cancer Syndrome?
Hereditary ovarian cancer syndrome is not one specific disease. It is a term that covers several inherited genetic conditions, each of which significantly raises a person's lifetime risk of developing ovarian cancer. These conditions are caused by gene changes a person is born with, passed down from a biological parent, and present in every cell of their body from birth.
Knowing which inherited condition and which gene are involved helps show how much risk may be increased, what other cancers may also be linked, and what doctors may recommend for screening or risk reduction. This is especially important for ovarian cancer, where inherited mutations play a bigger role than they do in many other cancers.
HBOC Syndrome, The Most Common Hereditary Ovarian Cancer Syndrome
HBOC is one of only three conditions designated as a CDC Tier 1 Genomic Application, meaning the evidence base for genetic screening and subsequent clinical intervention is strong enough to support population-level action. (CDC Genomics)
Lynch Syndrome and Ovarian Cancer Risk
Lynch syndrome is caused by changes in a group of genes called mismatch repair genes, including MLH1, MSH2, MSH6, and PMS2. Most people associate Lynch syndrome with colorectal cancer, and that association is correct. But Lynch syndrome also raises ovarian cancer risk by an estimated 4 to 12 percent lifetime risk, depending on which specific gene is involved.
Women with Lynch syndrome typically need gynecologic monitoring alongside their colorectal cancer surveillance. Lynch syndrome is also a CDC Tier 1 condition, meaning genetic testing is strongly supported for people who meet the eligibility criteria. (CDC Genomics, Lynch Syndrome)
Who Should Get Genetic Testing for Hereditary Ovarian Cancer Risk?
Major clinical organizations, including the American Cancer Society and the National Comprehensive Cancer Network, have established clear criteria for who should pursue hereditary ovarian cancer genetic testing. These criteria are based on personal and family history patterns that suggest an inherited syndrome may be present. (National Comprehensive Cancer Network)
Ovarian cancer has one of the strongest hereditary links, and testing is often recommended based on family history.
Clinical Guidelines on Who Qualifies
Hereditary ovarian cancer risk testing is generally recommended for people who have:
A personal history of ovarian cancer at any age
A mother, sister, or daughter who has had ovarian cancer
A family member with a confirmed BRCA1 or BRCA2 mutation
A personal or family history consistent with Lynch syndrome, such as multiple colorectal or endometrial cancers in close relatives
Breast cancer diagnosed before age 50, or triple-negative breast cancer at any age
Male breast cancer in any family member
Ashkenazi Jewish ancestry combined with any personal or family cancer history, since approximately 1 in 40 people of Ashkenazi Jewish descent carry a BRCA founder mutation
Meeting any of these criteria does not mean a mutation is definitely present, but it does make testing clinically appropriate and important for planning next steps if a mutation is found.
You Do Not Need a Diagnosis to Get Tested
Genetic testing for ovarian cancer risk is not only for people who have already been diagnosed with cancer. Many people pursue it proactively because of their family history, and that is exactly the right time to do it. The window for acting on a positive result is widest before a diagnosis occurs.
For individuals who are considering proactive testing, a genetic counselor can review family history, assess clinical criteria, and recommend the most appropriate testing panel. Your genetic information is private and protected, accessible only to you and your care team.
Get clarity on your inherited risk before a diagnosis does.
Kadance members receive access to hereditary cancer risk testing covering 26 clinically actionable genes, including BRCA1, BRCA2, and primary Lynch syndrome genes linked to hereditary ovarian cancer syndrome, plus genetic counseling to interpret positive results and plan next steps.
What Does Ovarian Cancer Genetic Testing Involve?
The process of hereditary ovarian cancer risk testing is more straightforward than many people expect. Testing has evolved significantly in the past decade; what once required multiple separate tests can now be done with a single sample.
What is Included in a Multi-Gene Panel
A hereditary cancer panel for ovarian cancer risk typically includes:
BRCA1 and BRCA2 (the primary HBOC syndrome genes)
MLH1, MSH2, MSH6, PMS2 (the Lynch syndrome genes)
BRIP1, RAD51C, RAD51D (moderate ovarian cancer risk genes)
PALB2, ATM, CHEK2 (breast and other cancer risk genes often included in ovarian cancer context)
How to Understand Your Test Results
Results from hereditary ovarian cancer risk testing are typically returned in two categories. Understanding what each means before you test can make a real difference in how you receive and process the information.
Positive Result: What It Means and What Happens Next
A positive result means a harmful inherited genetic change was identified in one of the tested genes. This is an actionable finding. It does not mean cancer will develop for certain, but it does mean your lifetime risk is significantly elevated and that clinical guidelines recommend specific steps, including enhanced surveillance, risk-reduction discussions, and informing family members who may want to consider testing.
After a positive result, you will work with a genetic counselor and relevant specialists, often a gynecologic oncologist for ovarian cancer risk. The plan that follows depends on which gene is involved, your age, your overall health, and your personal circumstances.
Negative Result: What It Does and Doesn't Rule Out
A negative result means no harmful gene change was found in the genes tested. This significantly reduces the likelihood of a hereditary ovarian cancer syndrome. But it does not eliminate cancer risk entirely. Sporadic ovarian cancer, the kind not caused by inherited mutations, can still occur. And if a specific mutation is known in your family, a genetic counselor should interpret your result carefully to make sure the test was designed to detect it.
For people with a strong family history and a negative result, genetic counselors may still recommend monitoring based on the family pattern, even without a confirmed mutation.
Variant of Uncertain Significance (VUS)
A variant of uncertain significance, often called a VUS, is a DNA change that was identified during testing but for which current science does not yet have enough evidence to say whether it is harmful or harmless. A VUS is not a positive result and should not be treated as one.
Not all laboratories report VUS findings. Some labs choose to report only results that are clinically actionable, meaning there is a clear next step to take. Others report VUS findings and monitor the scientific literature, since some VUS results are eventually reclassified as harmful or harmless as evidence accumulates. If your lab does not report VUS findings, your genetic counselor will focus only on results that have a clear clinical meaning.
Understanding Your Test Result
What each result means and what happens next
Result
What It Means
What Happens Next
Positive
Pathogenic mutation identified.
Cancer risk is significantly elevated.
Specialist referral, enhanced surveillance, and cascade testing for relatives may follow.
Negative
No mutation found in tested genes. Hereditary syndrome risk is reduced, but not every inherited cause can be fully ruled out.
Family-history monitoring may still apply. Sporadic risk remains and standard care continues.
VUS
DNA change found but not yet classifiable. This is not a positive result. Some labs report these findings; others do not, because they are not clinically actionable.
If reported, continue standard care and monitor for future reclassification updates.
Positive
What It Means
Pathogenic mutation identified.
Cancer risk is significantly elevated.
What Happens Next
Specialist referral, enhanced surveillance, and cascade testing for relatives may follow.
Negative
What It Means
No mutation found in tested genes. Hereditary syndrome risk is reduced, but not every inherited cause can be fully ruled out.
What Happens Next
Family-history monitoring may still apply. Sporadic risk remains and standard care continues.
VUS
What It Means
DNA change found but not yet classifiable. This is not a positive result. Some labs report these findings; others do not, because they are not clinically actionable.
What Happens Next
If reported, continue standard care and monitor for future reclassification updates.
A positive result changes clinical management. A negative result lowers concern but does not erase all risk. A VUS should not be treated as a confirmed hereditary cancer finding.
Happens After a Positive Hereditary Ovarian Cancer Risk Test?
A positive test result can help guide important clinical conversations and identify options that may not have been considered before. What those conversations and options look like depends on the gene involved and the individual's circumstances, but the pathway generally includes:
Referral to a gynecologic oncologist: Specialists in gynecologic cancers work with BRCA mutation and Lynch syndrome carriers to plan surveillance and risk-reduction strategies.
Ovarian cancer surveillance: For BRCA mutation carriers, this typically includes transvaginal ultrasound and CA-125 testing on a regular schedule, though surveillance alone has limited efficacy compared to risk-reducing surgery.
Risk-reducing salpingo-oophorectomy (RRSO): Removal of fallopian tubes and ovaries before cancer develops is the most effective risk-reduction option for BRCA1/BRCA2 carriers, reducing ovarian cancer risk by approximately 80–96%. Timing is individualized based on age, reproductive plans, and menopausal status.
Cascade testing: Informing and testing biological relatives who may have inherited the same mutation. A genetic counselor helps navigate this process.
Comprehensive cancer risk review: BRCA mutations also raise breast cancer risk; Lynch syndrome raises colorectal and endometrial cancer risk. A positive result triggers a multi-cancer surveillance and risk-reduction plan.
The goal of acting on a positive result is to narrow the window during which cancer could develop undetected, or to reduce the biological risk before cancer has the opportunity to develop.
Take control of your health with genetic counseling and testing.
Through a Kadance membership, individuals receive access to hereditary cancer risk testing, genetic counseling, and the clinical coordination to translate results into an informed action plan.
FAQ, Hereditary Ovarian Cancer Syndrome Questions
Is genetic testing for ovarian cancer covered by insurance?
Coverage varies by health plan and depends on whether testing is deemed medically necessary, typically based on personal or family history criteria. The Genetic Information Nondiscrimination Act (GINA) provides some federal protections against discrimination by health insurers based on genetic test results, but it does not guarantee that testing costs are covered. Pre-authorization requirements, documentation of family history, and a physician referral can affect coverage decisions. A genetic counselor can help clarify likely coverage and alternatives.
Can a negative BRCA test rule out all ovarian cancer risk?
No. A negative BRCA1 and BRCA2 test reduces hereditary ovarian cancer risk but does not eliminate it. Ovarian cancer can also be caused by mutations in other genes, such as Lynch syndrome genes, BRIP1, or RAD51C and RAD51D. And sporadic ovarian cancer, unrelated to any inherited mutation, can occur in anyone. A comprehensive single multi-gene panel gives a more complete picture than a BRCA-only test.
Should I tell my family if I test positive?
This is one of the most common and emotionally complex questions that follows a positive result. Each first-degree relative, meaning parents, siblings, and children, has a 50% chance of having inherited the same mutation. Sharing this information can give them the opportunity to pursue testing and take protective action. Genetic counselors are specifically trained to help people think through when, how, and what to share with family members, including how to support relatives who may not be ready to hear it.
The Knowledge You Have Now Can Change What Happens Later
The most valuable thing about hereditary ovarian cancer risk testing is not what it finds; it is when it finds it. A positive result before a diagnosis creates options. A positive result after a diagnosis changes the conversation. Proactive testing positions individuals to use information rather than react to it.
For anyone with a family history of ovarian cancer or related hereditary cancer patterns, the question is not whether testing is worth it. The evidence is clear that it is. The question is when to start.
Understand your risk. Start with what your DNA can tell you.
Learn how Kadance membership can connect you to hereditary cancer risk testing, genetic counseling, and a precision health framework designed to support informed decisions before a diagnosis makes them urgent.
.svg)
